ABOUT VELICEPT

Velicept Therapeutics, Inc. is a privately held, clinical development company focused on advancing best-in-class compounds with the potential to fill unmet medical needs. Its lead program, solabegron, is a highly differentiated novel compound being investigated for overactive bladder (OAB) and irritable bowel syndrome (IBS).

PIPELINE

Solabegron has completed and demonstrated positive results in initial Phase II clinical studies for the treatment of overactive bladder (OAB) in women and irritable bowel syndrome (IBS). Solabegron has completed and demonstrated positive results in initial Phase II clinical studies for the treatment of overactive bladder (OAB) in women and irritable bowel syndrome (IBS). Solabegron is currently being studied in 2 phase 2b studies evaluating both BID and novel QD formulations.

NEWS + EVENTS

Velicept Therapeutics Announces Positive Top-Line Phase 2b Results for Solabegron in the Treatment of Overactive Bladder (OAB)

Velicept Therapeutics Announces Positive Top-Line Phase 2b Results for Solabegron in the Treatment of Overactive Bladder (OAB) –  Study VEL-2002 further validates solabegron’s potential for best-in-class efficacy across multiple primary and secondary endpoints   Wayne, PA – March 28, 2019 – Velicept Therapeutics, a privately-held specialty pharmaceutical company dedicated to the development of best-in-class compounds […]